<p>LifeMD（纳斯达克股票代码：LFMD - 获取免费报告）在周三发布的报告中，Mizuho 的分析师将其目标价格从 8.00 美元下调至 6.00 美元，Benzinga 报道。该券商目前对该股票的评级为 “中性”。Mizuho 的目标价格暗示该公司股价有 50.00% 的上涨潜力。</p>
<ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
<p>其他一些研究公司也对 LFMD 发表了评论。华尔街 Zen 在 8 月 2 日的研究报告中将 LifeMD 的股票评级从 “买入” 下调至 “持有”。Zacks Research 在 9 月 5 日的报告中将 LifeMD 的评级从 “强烈卖出” 上调至 “持有”。KeyCorp 在 8 月 6 日的研究报告中将 LifeMD 的目标价格从 14.00 美元下调至 12.00 美元，并给予该公司 “增持” 评级。Lake Street Capital 在周二的研究报告中将 LifeMD 的目标价格从 14.00 美元下调至 8.00 美元，并给予该公司 “买入” 评级。最后，BTIG Research 在周二的报告中将 LifeMD 的目标价格从 18.00 美元下调至 10.00 美元，并给予该股票 “买入” 评级。六位投资分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 10.57 美元。</p>
<p><strong>获取我们对 LifeMD 的最新分析</strong></p>
<h2>LifeMD 股价下跌 2.2%</h2>
<ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
<p>LFMD 在周三开盘价为 4.00 美元。该公司的速动比率为 0.72，流动比率为 0.77，债务与股本比率为 9.21。LifeMD 的 52 周低点为 3.43 美元，52 周高点为 15.84 美元。该公司的 50 日移动平均线为 6.01 美元，200 日移动平均线为 8.68 美元。该公司的市值为 1.8967 亿美元，市盈率为-23.54，贝塔值为 1.57。</p>
<p>LifeMD（纳斯达克股票代码：LFMD - 获取免费报告）最近于 11 月 17 日发布了季度财报。该公司报告每股收益为（0.10 美元），低于市场共识预期的（0.06 美元）4 美分。该公司在本季度的收入为 6017 万美元，而分析师预期为 6207 万美元。在去年同期，该公司每股收益为 0.09 美元。LifeMD 已设定 2025 财年的每股收益指导。2025 年第四季度的每股收益指导。研究分析师平均预测 LifeMD 在当前年度的每股收益为-0.56 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>LifeMD 因其 GLP-1 产品有望大幅上涨</li>
</ul>
<p>在其他 LifeMD 的新闻中，内部人士 Nicholas P. Alvarez 在 9 月 10 日的交易中出售了 75,000 股该公司的股票。股票以平均价格 5.92 美元出售，总交易额为 444,000.00 美元。交易后，该内部人士在公司持有 605,000 股，价值约为 3,581,600 美元。此次交易使其持股减少了 11.03%。该交易已在向 SEC 提交的文件中披露，SEC 网站上可以获取。公司内部人士持有该公司 18.40% 的股份。</p>
<h2>LifeMD 的机构交易</h2>
<p>机构投资者最近调整了对该公司的持股。Arrowstreet Capital Limited Partnership 在第二季度将其在 LifeMD 的持股增加了 1,767.8%。Arrowstreet Capital Limited Partnership 现在拥有 434,937 股该公司的股票，价值 592.4 万美元，此前在该期间内增加了 411,651 股。摩根大通在第二季度将其在 LifeMD 的持股增加了 581.2%。摩根大通现在拥有 412,571 股该公司的股票，价值 561.9 万美元，此前在该期间内购买了 352,004 股。Jump Financial LLC 在第二季度将其在 LifeMD 的持股增加了 205.0%。Jump Financial LLC 现在拥有 515,052 股该公司的股票，价值 701.5 万美元，此前在上一季度购买了 346,171 股。Invesco Ltd.在第二季度将其在 LifeMD 的持股增加了 1,904.0%。Invesco Ltd.现在拥有 327,080 股该公司的股票，价值 445.5 万美元，此前在该期间内购买了 310,759 股。最后，Nuveen LLC 在第一季度获得了 LifeMD 的新股份，价值约为 154.5 万美元。目前 35.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>LifeMD 公司简介</h2>
<p>（获取免费报告）</p>
<p>LifeMD, Inc 是一家直接面向患者的远程医疗公司，连接消费者与美国的医疗专业人员以提供医疗服务。该公司提供的远程医疗平台包括 RexMD，这是一个男性远程医疗品牌，提供由持证医生提供的多种男性健康需求的虚拟医疗治疗；ShapiroMD 提供虚拟医疗治疗、处方药、专利医生配方的非处方产品、外用复合药物和治疗男性和女性脱发的医疗设备；NavaMD 是一个女性导向的远程皮肤科，提供来自皮肤科医生和其他提供者的虚拟医疗治疗；以及处方口服和外用复合药物以治疗衰老和痤疮；Cleared 提供个性化的过敏、哮喘和免疫治疗，包括环境和食物过敏的家庭测试、过敏和哮喘的处方以及治疗慢性过敏的免疫疗法。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票比 LifeMD 更好</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>买家需谨慎：Carvana 正在引发汽车贷款危机</li>
<li>什么是内幕交易？你可以从内幕交易中学到什么</li>
<li>医疗保健轮换正在进行：三只股票引领潮流</li>
<li>什么是股息挑战者？</li>
<li>美敦力股票找到立足点——现在正在获得动能</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 LifeMD 吗？</h2>
<p>在考虑 LifeMD 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 LifeMD 并不在名单上。</p>
<p>虽然 LifeMD 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LFMD

<p>瑞穗证券将 LifeMD 的目标股价从 8.00 美元下调至 6.00 美元，维持 “中性” 评级。其他分析师的评级各不相同，有的下调评级，有的维持买入评级。LifeMD 的股票开盘价为 4.00 美元，市值为 1.8967 亿美元。机构投资者显著增加了他们的持股。该公司在美国作为远程医疗服务提供商运营</p>

<p>LifeMD (NASDAQ:LFMD - Get Free Report) had its price objective decreased by analysts at Mizuho from $8.00 to $6.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a &#34;neutral&#34; rating on the stock. Mizuho's price objective would suggest a potential upside of 50.00% from the company's previous close.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克股票代码：LFMD - 获取免费报告）在周三发布的报告中，Mizuho 的分析师将其目标价格从 8.00 美元下调至 6.00 美元，Benzinga 报道。该券商目前对该股票的评级为 “中性”。Mizuho 的目标价格暗示该公司股价有 50.00% 的上涨潜力。</p>
</div><ul>
<li>Can the New CEO Revive This Struggling Telehealth Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
</div><p>A number of other research firms have also commented on LFMD. Wall Street Zen lowered shares of LifeMD from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, August 2nd. Zacks Research raised LifeMD from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, September 5th. KeyCorp reduced their price objective on LifeMD from $14.00 to $12.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, August 6th. Lake Street Capital decreased their price objective on LifeMD from $14.00 to $8.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday. Finally, BTIG Research dropped their target price on LifeMD from $18.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $10.57.</p>
<div class="lb-trans"><p>其他一些研究公司也对 LFMD 发表了评论。华尔街 Zen 在 8 月 2 日的研究报告中将 LifeMD 的股票评级从 “买入” 下调至 “持有”。Zacks Research 在 9 月 5 日的报告中将 LifeMD 的评级从 “强烈卖出” 上调至 “持有”。KeyCorp 在 8 月 6 日的研究报告中将 LifeMD 的目标价格从 14.00 美元下调至 12.00 美元，并给予该公司 “增持” 评级。Lake Street Capital 在周二的研究报告中将 LifeMD 的目标价格从 14.00 美元下调至 8.00 美元，并给予该公司 “买入” 评级。最后，BTIG Research 在周二的报告中将 LifeMD 的目标价格从 18.00 美元下调至 10.00 美元，并给予该股票 “买入” 评级。六位投资分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 10.57 美元。</p>
</div><p><strong>Get Our Latest Analysis on LifeMD</strong></p>
<div class="lb-trans"><p><strong>获取我们对 LifeMD 的最新分析</strong></p>
</div><h2>LifeMD Trading Down 2.2%</h2>
<div class="lb-trans"><h2>LifeMD 股价下跌 2.2%</h2>
</div><ul>
<li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
</div><p>LFMD opened at $4.00 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. LifeMD has a 52 week low of $3.43 and a 52 week high of $15.84. The business's 50 day moving average is $6.01 and its two-hundred day moving average is $8.68. The firm has a market cap of $189.67 million, a price-to-earnings ratio of -23.54 and a beta of 1.57.</p>
<div class="lb-trans"><p>LFMD 在周三开盘价为 4.00 美元。该公司的速动比率为 0.72，流动比率为 0.77，债务与股本比率为 9.21。LifeMD 的 52 周低点为 3.43 美元，52 周高点为 15.84 美元。该公司的 50 日移动平均线为 6.01 美元，200 日移动平均线为 8.68 美元。该公司的市值为 1.8967 亿美元，市盈率为-23.54，贝塔值为 1.57。</p>
</div><p>LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same period in the prior year, the firm earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that LifeMD will post -0.56 EPS for the current year.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克股票代码：LFMD - 获取免费报告）最近于 11 月 17 日发布了季度财报。该公司报告每股收益为（0.10 美元），低于市场共识预期的（0.06 美元）4 美分。该公司在本季度的收入为 6017 万美元，而分析师预期为 6207 万美元。在去年同期，该公司每股收益为 0.09 美元。LifeMD 已设定 2025 财年的每股收益指导。2025 年第四季度的每股收益指导。研究分析师平均预测 LifeMD 在当前年度的每股收益为-0.56 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>LifeMD Can Surge on Its GLP-1 Offerings</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 因其 GLP-1 产品有望大幅上涨</li>
</ul>
</div><p>In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares in the company, valued at approximately $3,581,600. The trade was a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 18.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他 LifeMD 的新闻中，内部人士 Nicholas P. Alvarez 在 9 月 10 日的交易中出售了 75,000 股该公司的股票。股票以平均价格 5.92 美元出售，总交易额为 444,000.00 美元。交易后，该内部人士在公司持有 605,000 股，价值约为 3,581,600 美元。此次交易使其持股减少了 11.03%。该交易已在向 SEC 提交的文件中披露，SEC 网站上可以获取。公司内部人士持有该公司 18.40% 的股份。</p>
</div><h2>Institutional Trading of LifeMD</h2>
<div class="lb-trans"><h2>LifeMD 的机构交易</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership lifted its holdings in LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company's stock valued at $5,924,000 after acquiring an additional 411,651 shares during the period. JPMorgan Chase &amp; Co. grew its stake in shares of LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase &amp; Co. now owns 412,571 shares of the company's stock worth $5,619,000 after purchasing an additional 352,004 shares during the period. Jump Financial LLC increased its holdings in shares of LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company's stock valued at $7,015,000 after purchasing an additional 346,171 shares in the last quarter. Invesco Ltd. lifted its stake in shares of LifeMD by 1,904.0% in the second quarter. Invesco Ltd. now owns 327,080 shares of the company's stock valued at $4,455,000 after purchasing an additional 310,759 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of LifeMD in the first quarter valued at about $1,545,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Arrowstreet Capital Limited Partnership 在第二季度将其在 LifeMD 的持股增加了 1,767.8%。Arrowstreet Capital Limited Partnership 现在拥有 434,937 股该公司的股票，价值 592.4 万美元，此前在该期间内增加了 411,651 股。摩根大通在第二季度将其在 LifeMD 的持股增加了 581.2%。摩根大通现在拥有 412,571 股该公司的股票，价值 561.9 万美元，此前在该期间内购买了 352,004 股。Jump Financial LLC 在第二季度将其在 LifeMD 的持股增加了 205.0%。Jump Financial LLC 现在拥有 515,052 股该公司的股票，价值 701.5 万美元，此前在上一季度购买了 346,171 股。Invesco Ltd.在第二季度将其在 LifeMD 的持股增加了 1,904.0%。Invesco Ltd.现在拥有 327,080 股该公司的股票，价值 445.5 万美元，此前在该期间内购买了 310,759 股。最后，Nuveen LLC 在第一季度获得了 LifeMD 的新股份，价值约为 154.5 万美元。目前 35.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>LifeMD Company Profile</h2>
<div class="lb-trans"><h2>LifeMD 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.</p>
<div class="lb-trans"><p>LifeMD, Inc 是一家直接面向患者的远程医疗公司，连接消费者与美国的医疗专业人员以提供医疗服务。该公司提供的远程医疗平台包括 RexMD，这是一个男性远程医疗品牌，提供由持证医生提供的多种男性健康需求的虚拟医疗治疗；ShapiroMD 提供虚拟医疗治疗、处方药、专利医生配方的非处方产品、外用复合药物和治疗男性和女性脱发的医疗设备；NavaMD 是一个女性导向的远程皮肤科，提供来自皮肤科医生和其他提供者的虚拟医疗治疗；以及处方口服和外用复合药物以治疗衰老和痤疮；Cleared 提供个性化的过敏、哮喘和免疫治疗，包括环境和食物过敏的家庭测试、过敏和哮喘的处方以及治疗慢性过敏的免疫疗法。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than LifeMD</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>Buyer Beware: Carvana Is Driving an Auto Lending Crisis</li>
<li>What is Insider Trading? What You Can Learn from Insider Trading</li>
<li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li>
<li>What Are Dividend Challengers?</li>
<li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 LifeMD 更好</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>买家需谨慎：Carvana 正在引发汽车贷款危机</li>
<li>什么是内幕交易？你可以从内幕交易中学到什么</li>
<li>医疗保健轮换正在进行：三只股票引领潮流</li>
<li>什么是股息挑战者？</li>
<li>美敦力股票找到立足点——现在正在获得动能</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in LifeMD Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LifeMD 吗？</h2>
</div><p>Before you consider LifeMD, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LifeMD 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 LifeMD 并不在名单上。</p>
</div><p>While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LifeMD 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

瑞穗将 LifeMD（NASDAQ:LFMD）的目标价下调至 6.00 美元